A number of other brokerages have also weighed in on CLLS. BTIG Research initiated coverage on shares of Cellectis in a report on Friday, August 9th. They issued a buy rating and a $37.00 price objective for the company. ValuEngine upgraded shares of Cellectis from a sell rating to a hold rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Cellectis from a sell rating to a hold rating in a report on Monday, August 26th. Finally, Goldman Sachs Group set a $20.00 price objective on shares of Cellectis and gave the stock a hold rating in a report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $31.33.
NASDAQ:CLLS traded down $0.16 during mid-day trading on Tuesday, reaching $13.53. 88,900 shares of the company’s stock traded hands, compared to its average volume of 99,222. Cellectis has a 12-month low of $9.50 and a 12-month high of $22.66. The firm has a market capitalization of $564.16 million, a price-to-earnings ratio of -7.01 and a beta of 1.77. The company has a 50 day moving average price of $11.10 and a 200-day moving average price of $14.10. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.99 and a quick ratio of 7.93.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Recommended Story: Most Active Stocks: Dollar Volume vs Share Volume
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.